Artivion(AORT)

Focus: Artivion is a publicly traded medical device and tissue engineering company focused on cardiovascular solutions, including surgical devices, allograft tissues, and hemostatic systems. With ~$354M in revenue (FY2025) and 1,001–5,000 employees, it operates as a specialized cardiovascular device manufacturer.

Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

1001-5000

Open Jobs

About Artivion

AI assessmentNot Hiring

No open roles listed right now. Follow Artivion to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$354M

Pipeline & Clinical Trials

AMDS

Acute Aortic Dissection

N/A

Clinical Trials (2)

NCT03397251DARTS I: Feasibility, Safety, and Performance Trial

N/A

Help build intelligence for Artivion

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Recent FDA approval momentum: AMDS hybrid prosthesis, NEXUS stent graft system, and other cardiovascular devices cleared in mid-2026, signaling commercial execution and regulatory success.
Established revenue base of $354M (FY2025, +12.7% YoY) provides salary stability and infrastructure typical of larger biotech, not early-stage volatility.
Focused portfolio in high-acuity cardiovascular space (aortic dissection, valve disease, critical limb ischemia) offers deep clinical impact and specialized expertise.

Watch Out For

Persistent net losses ($30.7M in FY2025, $19.2M in FY2024) despite revenue growth indicate margin pressure or R&D heavy spending; no hiring signals detected (0 active jobs listed).
R&D spend declined 25% YoY ($39M FY2024 → $29M FY2025) while pipeline remains largely in development phase (only 1 Phase 3 trial); suggests tightening investment or deprioritization.
Cash position eroding ($59M FY2024 → $53M FY2025) with negative free cash flow and no disclosed NIH/private funding; sustainability risk if approvals don't translate to revenue quickly.

Generated by Claude from Artivion's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

NCT03035643DARTS I Feasibility Study

N/A

PhotoFix

Vascular Diseases

N/A

Clinical Trials (2)

NCT05314868Retrospective Evaluation of Photo-oxidized Decellularized Bovine Pericardium in Cardiac Repair or Reconstruction Surgery

N/A

NCT03669042Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vascular Surgery

N/A

PerClot Polysaccharide Hemostatic System

Blood Loss, Surgical

N/A

Clinical Trials (1)

NCT02359994Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System

N/A

Arcevo LSA

Aortic Arch Aneurysm

N/A

Clinical Trials (1)

NCT07089576Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA

N/A

Chord-X

Mitral Regurgitation

N/A

Clinical Trials (1)

NCT07413926Mitral Valve Repair With the Chord-X System: A Long Term Evaluation

N/A

Cryopreserved Saphenous Vein Allograft

Critical Limb Ischemia

N/A

Clinical Trials (1)

NCT01799811Cryopreserved Saphenous Vein Allograft in Patients With Critical Limb Ischemia for Peripheral Revascularization

N/A

On-X Aortic Mechanical Valve

Aortic Valve Disease

Phase 3

Clinical Trials (1)

NCT04142658PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 1984

Portfolio: 9 clinical trials

Top TAs: Cardiovascular, Nephrology

Publications: 4 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Cardiovascular

5 pipeline

Nephrology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$354M13%

R&D Spend

$29M(8%)26%

Net Income

-$31M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 3 crawl cycles

Research Publications(4)

Recent peer-reviewed publications with author affiliations at this company

Cardiac rhabdomyoma: an uncommon culprit in sudden infant death.

Forensic science, medicine, and pathology

2024

PMID:38963610

Branched Endovascular Thoracoabdominal Aneurysm Repair Under Electromagnetic Guidance in an in Vitro Model.

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Artivion(AORT)

About Artivion

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Artivion(10)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Research Publications(4)